Wells Fargo analyst Tiago Fauth maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of $3.00.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report) yesterday and set a price target of ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...

Pliant Technologies’ CrewCom CB2 Professional Wireless Intercom system is a full-duplex, install-friendly and feature-packed solution for small to mid-level applications requiring a reliable, great ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...

Pliant Therapeutics paused enrollment in its BEACON-IPF Phase 2b trial of bexotegrast after a safety board review. Get 5 stock picks identified before their biggest breakouts, identified by the ...